The Invisible Child of Personalised Medicine

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Standard

The Invisible Child of Personalised Medicine. / Ó Cathaoir, Katharina Eva.

2019. Abstract from Healthcare disparities: Disruptive healthcare technologies and the patient, Manchester, United Kingdom.

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Harvard

Ó Cathaoir, KE 2019, 'The Invisible Child of Personalised Medicine', Healthcare disparities: Disruptive healthcare technologies and the patient, Manchester, United Kingdom, 13/06/2019 - 14/06/2019.

APA

Ó Cathaoir, K. E. (2019). The Invisible Child of Personalised Medicine. Abstract from Healthcare disparities: Disruptive healthcare technologies and the patient, Manchester, United Kingdom.

Vancouver

Ó Cathaoir KE. The Invisible Child of Personalised Medicine. 2019. Abstract from Healthcare disparities: Disruptive healthcare technologies and the patient, Manchester, United Kingdom.

Author

Ó Cathaoir, Katharina Eva. / The Invisible Child of Personalised Medicine. Abstract from Healthcare disparities: Disruptive healthcare technologies and the patient, Manchester, United Kingdom.

Bibtex

@conference{513abce67d374782bc86e191a148147d,
title = "The Invisible Child of Personalised Medicine",
abstract = "Personalised Medicine is increasingly promoted as cutting edge health technology that will improve patient outcomes through tailored treatment and diagnosis. In several countries, it is already poised to become an integral part of public healthcare, which underscores the need for adequate reflection. Yet, as this paper will emphasise, existing laws and policies often neglect the particular legal and ethical issues facing children.The paper maps the potential risks facing children through the lens of equality. It suggests that personalised medicine may result in inequalities in terms of access to treatment and information. This is particularly true where parents are the sole decision makers. Furthermore, personalised medicine may generate inequalities for the future adult, including potential discrimination. This raises questions such as, should children’s genomes be sequenced before they can provide consent, and should sequencing be permitted on healthy children?Finally, the paper makes recommendations for how inequalities could be mitigated in a manner that upholds children’s best interests. This includes strengthening children’s participation while limiting the implications of parents’ decisions, and ensuring involvement of families belonging to minority ethnic groups. New technical solutions should be developed to ensure that data and results are kept accessible for children when needed for their care",
author = "{{\'O} Cathaoir}, {Katharina Eva}",
year = "2019",
language = "English",
note = "Healthcare disparities: Disruptive healthcare technologies and the patient ; Conference date: 13-06-2019 Through 14-06-2019",

}

RIS

TY - ABST

T1 - The Invisible Child of Personalised Medicine

AU - Ó Cathaoir, Katharina Eva

PY - 2019

Y1 - 2019

N2 - Personalised Medicine is increasingly promoted as cutting edge health technology that will improve patient outcomes through tailored treatment and diagnosis. In several countries, it is already poised to become an integral part of public healthcare, which underscores the need for adequate reflection. Yet, as this paper will emphasise, existing laws and policies often neglect the particular legal and ethical issues facing children.The paper maps the potential risks facing children through the lens of equality. It suggests that personalised medicine may result in inequalities in terms of access to treatment and information. This is particularly true where parents are the sole decision makers. Furthermore, personalised medicine may generate inequalities for the future adult, including potential discrimination. This raises questions such as, should children’s genomes be sequenced before they can provide consent, and should sequencing be permitted on healthy children?Finally, the paper makes recommendations for how inequalities could be mitigated in a manner that upholds children’s best interests. This includes strengthening children’s participation while limiting the implications of parents’ decisions, and ensuring involvement of families belonging to minority ethnic groups. New technical solutions should be developed to ensure that data and results are kept accessible for children when needed for their care

AB - Personalised Medicine is increasingly promoted as cutting edge health technology that will improve patient outcomes through tailored treatment and diagnosis. In several countries, it is already poised to become an integral part of public healthcare, which underscores the need for adequate reflection. Yet, as this paper will emphasise, existing laws and policies often neglect the particular legal and ethical issues facing children.The paper maps the potential risks facing children through the lens of equality. It suggests that personalised medicine may result in inequalities in terms of access to treatment and information. This is particularly true where parents are the sole decision makers. Furthermore, personalised medicine may generate inequalities for the future adult, including potential discrimination. This raises questions such as, should children’s genomes be sequenced before they can provide consent, and should sequencing be permitted on healthy children?Finally, the paper makes recommendations for how inequalities could be mitigated in a manner that upholds children’s best interests. This includes strengthening children’s participation while limiting the implications of parents’ decisions, and ensuring involvement of families belonging to minority ethnic groups. New technical solutions should be developed to ensure that data and results are kept accessible for children when needed for their care

M3 - Conference abstract for conference

ER -

ID: 222759524